About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

SUBSCRIBE TO LASER FOCUS WORLD MAGAZINE

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

SUBSCRIBE TO LASER FOCUS WORLD NEWSLETTERS

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

SUBMISSION GUIDELINES

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

Professor Andrea M. Armani, University of Southern California
Ruti Ben-Shlomi, Ph.D., LightSolver
James Butler, Ph.D., Hamamatsu
Natalie Fardian-Melamed, Ph.D., Columbia University
Justin Sigley, Ph.D., AmeriCOM
Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
Professor Stephen Sweeney, University of Glasgow
Mohan Wang, Ph.D., University of Oxford
Professor Xuchen Wang, Harbin Engineering University
Professor Stefan Witte, Delft University of Technology

Indicators

Markets:

News

Is Biotech Immunocore About To Make A 25% Price Move?

By: MarketBeat

February 07, 2023 at 07:00 AM EST

Is Biotech Immunocore About To Make A 25% Price Move?

The biotech industry has stood out in recent months, with Immunocore Holdings PLC (NASDAQ: IMCR) among the group’s top price performers.

The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.

But less well-known companies, such as Exact Sciences Corp. (NASDAQ: EXAS), a top holding in Cathie Woods’ Ark Innovation ETF (NYSEARCA: ARKK), along with numerous small caps, have been notching strong rallies.

U.K.-based Immunocore develops immunotherapies to treat cancer and infectious and autoimmune diseases.

Its sole product currently on the market is Kimmtrak, a treatment for melanoma. However, Immunocore has six other potential drugs in its pipeline, drawing from the same technologies underpinning Kimmtrack.

Developing More Treatments Using Existing Platform

In addition to that compound, the biotech is working on six treatments using the same technology, known as T-cell receptor therapy. With the new products in the pipeline, the company aims to treat other forms of cancer, autoimmune diseases, and infectious diseases, such as hepatitis.

The company reports its fourth quarter on March 2 ahead of the market opening. Wall Street is eyeing a loss of $0.03 per share on revenue of $38.68 million. That would be a year-over-year revenue increase of 335%.

In its most recent earnings report, the company said total net product and net pre-product revenue from the sale of Kimmtrack and tebentafusp, its chemical name, was $40.4 million in the three months ending September 30, 2022. The company also had $5.451 million in collaboration revenue from discovery partnerships with Genentech, Eli Lilly and Company (NYSE: LLY), and GSK PLC (NYSE: GSK) to develop new cancer therapies Immunocore’s technology platform.

Its total revenue of $45,871 in the most recent quarter was a 476% year-over-year increase. That stands to reason, as Kimmtrak only received FDA approval in January 2022. Revenue ramped up in the quarter ending in March 2022 and grew at triple-digit rates in the past three quarters.

The company swung to profitability in the most recent quarter, earning $0.13 per share.

MarketBeat earnings data for Immucore show the company significantly topped earnings and sales views in the past three quarters.

For the full year of 2022, Immunocore is expected to report a loss of $0.40 per share, narrowed from the 2021 loss of $4.13 per share. That loss is expected to remain at $0.40 a share this year.

Immunocore has posted strong, market-beating gains in the past year. The stock is up 163.05% on a one-year basis. It’s up 16.01% in the past month and 12.06% in the past three months.

Tracked By Nasdaq Biotech Index

The stock is not a component of any major indexes, but it’s part of the Nasdaq Biotechnology Index, as tracked by the Invesco Nasdaq Biotechnology ETF (NYSEARCA: IBBQ). It only comprises 0.15% of fund assets, but it never hurts to be part of an index. That means ETFs tracking the index have to buy enough of the stock’s shares to maintain balance.

The buyers are clearly in charge. According to MarketBeat institutional investor data for Immunocore, in the past 12 months, 43 institutional buyers accounted for inflows of $179.00 million. 19 institutional sellers accounted for outflows of $36.34 million during that time.

Is Biotech Immunocore About To Make A 25% Price Move?

The stock broke out of a cup-shaped base with a buy point above $61.32 in late October, then rallied to a high of $69.06 on November 18 before retreating into a new consolidation. The current base is taking a cup-with-handle shape with a potential buy point just above $65. It’s hit resistance between $64 and $65 in the past three sessions.

Although Immunocore is not yet profitable, the institutional ownership data and recent uptrends signal that the stock has the potential to rise further. Analysts have a price target of $79.13, representing an upside of 25.18%. Analysts have a “buy” rating on the stock.

Recent Quotes

Symbol	Price	Change (%)
GOOG	247.18	+0.61 (0.25%)

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.